Zura Bio (ZURA) AI Stock Analysis

• Market Cap: $87.86M
• Dividend Yield: N/A
• Average Volume (3M): 936.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: N/A
• EPS Growth: 53.92%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 61,874,996
• 10 Day Avg. Volume: 329,824
• 30 Day Avg. Volume: 936,293
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.43
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.57
• 1Y Price Target: $3.00
• Price Target Upside: 112.77% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 43 Neutral
• Price Target: ―

Zura Bio's overall stock score is driven by significant financial challenges, including no revenue generation and consistent losses despite a strong cash position and no debt. While technical indicators suggest some short-term bullish trends, the negative P/E ratio and lack of dividends underscore the valuation concerns. The company's ability to generate revenue and improve operational efficiency will be crucial for future performance.

Positive Factors

Biological Rationale

There is a strong biological rationale for tibulizumab in treating hidradenitis suppurativa, which adds confidence to its potential success.

Clinical Trials

The timely execution of the Ph 2 TibuSHIELD trial is seen as an important milestone advancing ZURA’s position in the evolving HS landscape.

Company Progress

The initiation of the TibuSHIELD trial with the first clinical site activated earlier than expected is encouraging for the company's progress.

Negative Factors

Competitive Pressure

Dual IL-17A/F inhibitors have demonstrated impressive efficacy in late-stage trials, raising the bar for efficacy compared to IL-17A-only inhibitors.

Efficacy Challenges

The ianalumab study did not achieve predefined efficacy thresholds, which was a significant near-term catalyst for Zura Bio Limited.

Skepticism in Drug Combination

Skepticism exists that the fusion of an IL-17A-only inhibitor with a BAFF inhibitor would be advantageous in HS, given the intensifying competition and high benchmark set by IL-17A/F dual inhibitors.

Zura Bio Business Overview & Revenue Model

Company Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

How the Company Makes Money

Zura Bio generates revenue through the development and commercialization of its proprietary drug candidates. The company's primary revenue streams include licensing agreements, partnerships with other pharmaceutical companies, and potential sales of successfully developed therapies. Zura Bio collaborates with strategic partners for clinical development, regulatory approval, and distribution of its products, which can result in milestone payments and royalties. Additionally, the company may engage in research and development collaborations that provide funding and resource sharing to advance its product pipeline.

Zura Bio Financial Statement Overview

Summary

Zura Bio is facing financial difficulties with no revenue generation and increasing losses. The strong cash position and absence of debt are positives, providing financial stability in the short term. However, the company must address its operational inefficiencies and explore revenue generation strategies to ensure long-term viability. The current trajectory is unsustainable without a shift in operational or strategic direction.

Income Statement

Zura Bio has consistently reported zero revenue over the past three years, with increasing net losses. This reflects a challenging financial position in terms of generating income. The negative EBIT and EBITDA margins further highlight inefficiencies in cost management or lack of operational revenues.

Balance Sheet

The balance sheet shows a strong cash position with no debt, which provides a buffer against operational losses. The company's equity has significantly improved over the years, moving from negative to positive, indicating some financial recovery. However, the lack of revenue generation is a concern despite the strong cash reserves.

Cash Flow

Operating cash flow remains negative, reflecting ongoing operational challenges. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. While financing cash flow is positive, suggesting successful fundraising efforts, reliance on external financing could be risky without revenue improvement.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
EBITDA	-52.39M	-60.56M	-27.33M	8.42M
Net Income	-45.39M	-60.36M	3.55M	8.42M
Balance Sheet
Total Assets	179.53M	100.84M	141.51M	4.72M
Cash, Cash Equivalents and Short-Term Investments	176.50M	99.81M	13.79K	4.72M
Total Debt	0.00	0.00	355.60K	0.00
Total Liabilities	19.51M	21.29M	14.82M	39.00K
Stockholders Equity	146.81M	59.33M	-32.06M	4.68M
Cash Flow
Free Cash Flow	-28.15M	-23.05M	-13.07M	-1.10M
Operating Cash Flow	-28.08M	-15.05M	-1.07M	-1.10M
Investing Cash Flow	-5.08M	-8.00M	-12.00M	-139.38M
Financing Cash Flow	109.84M	121.29M	355.60K	141.21M

Zura Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.41
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Negative. The current price of 1.41 is below the 20-day moving average (MA) of 1.56, above the 50-day MA of 1.33, and below the 200-day MA of 1.87, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 47.50 is Neutral, neither overbought nor oversold. The STOCH value of 30.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZURA.

Zura Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRBU	52 Neutral	$159.04M	―	-52.76%	―	-70.31%	-11.68%
Sector *	51 Neutral	$7.35B	-0.20	-44.86%	2.33%	28.96%	-1.05%
ANIX	49 Neutral	$95.99M	―	-61.14%	―	―	-2.11%
ZURA	43 Neutral	$87.86M	―	-62.34%	―	―	53.92%
ATOS	36 Underperform	$101.66M	―	-34.87%	―	―	11.95%
HLVX	35 Underperform	$103.54M	―	-40.31%	―	―	57.64%
ELTX	30 Underperform	$150.31M	―	-9999.00%	―	―	-4.60%

Zura Bio Corporate Events

Zura Bio to Participate in Global Healthcare Conference

On February 24, 2025, Zura Bio announced its participation in the Leerink Partners Global Healthcare Conference scheduled for March 11, 2025. The company’s senior leadership will engage in a fireside chat and host investor meetings, reflecting its proactive approach to engaging with stakeholders and potentially enhancing its market visibility.